At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALMR Alamar Biosciences
Post-Mkt 10-26 17:44:10 EDT
30.39
-0.30
-0.98%
盘后30.39
+0.000.00%
16:04 EDT
High31.24Low30.01Vol634.03K
Open30.65D1 Closing30.69Amplitude4.01%
Mkt Cap2.11BTradable Cap1.20BTotal Shares69.31M
T/O19.34MT/O Rate1.61%Tradable Shares39.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Qiming Corporate GP VI and Affiliates Report Disposal of $10.25 Million in Alamar Biosciences Common Shares
Reuters  ·  10-24 07:36
Qiming Corporate GP VI and Affiliates Report Disposal of $10.25 Million in Alamar Biosciences Common Shares
Qiming Corporate GP VI Reports Sale of $5.95 Million in Alamar Biosciences Common Shares
Reuters  ·  10-22
Qiming Corporate GP VI Reports Sale of $5.95 Million in Alamar Biosciences Common Shares
Cathie Wood’s ARK Investment buys 101K shares of Alamar Biosciences today
TIPRANKS  ·  10-13
Cathie Wood’s ARK Investment buys 101K shares of Alamar Biosciences today
Alamar Biosciences to Report Q3 2026 Results After Market Close, Host Webcast Call
Reuters  ·  10-09
Alamar Biosciences to Report Q3 2026 Results After Market Close, Host Webcast Call
Alamar Biosciences Names Former GRAIL CEO Bob Ragusa to Board
Reuters  ·  10-06
Alamar Biosciences Names Former GRAIL CEO Bob Ragusa to Board
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
THOMSON REUTERS  ·  10-06
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Nightingale Health Signs USD 6.5 Million Proteomics Services Deal with Michael J. Fox Foundation
Reuters  ·  10-01
Nightingale Health Signs USD 6.5 Million Proteomics Services Deal with Michael J. Fox Foundation
Lancet study using Alamar’s technology reveals divergent responses to Alzheimers
TIPRANKS  ·  09-25
Lancet study using Alamar’s technology reveals divergent responses to Alzheimers
Alamar Biosciences Says Lancet Neurology Study Tracks 130 Plasma Biomarkers in Real-World Lecanemab-Treated Alzheimer’s Patients
Reuters  ·  09-25
Alamar Biosciences Says Lancet Neurology Study Tracks 130 Plasma Biomarkers in Real-World Lecanemab-Treated Alzheimer’s Patients
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
THOMSON REUTERS  ·  09-25
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
US Research Roundup-Autozone, General Mills, JPMorgan
Reuters  ·  09-24
US Research Roundup-Autozone, General Mills, JPMorgan
Alamar Biosciences Inc : Leerink Partners Raises Target Price to $45 from $35
THOMSON REUTERS  ·  09-24
Alamar Biosciences Inc : Leerink Partners Raises Target Price to $45 from $35
Alamar Biosciences rises 9.4%
TIPRANKS  ·  09-18
Alamar Biosciences rises 9.4%
Alamar Biosciences Director Robert P. Ragusa Files Initial Beneficial Ownership Statement
Reuters  ·  09-04
Alamar Biosciences Director Robert P. Ragusa Files Initial Beneficial Ownership Statement
Alamar Biosciences Appoints Robert Ragusa to Board
Reuters  ·  09-02
Alamar Biosciences Appoints Robert Ragusa to Board
Alamar Biosciences Price Target Raised to $32.00/Share from $28.00 by Stifel
Dow Jones  ·  08-12
Alamar Biosciences Price Target Raised to $32.00/Share from $28.00 by Stifel
Top Midday Gainers
MT Newswires Live  ·  08-12
Top Midday Gainers
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Benzinga Earnings  ·  08-12
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences up over 18%, on Track for Record High Close and Record Percent Increase
Dow Jones  ·  08-11
Alamar Biosciences up over 18%, on Track for Record High Close and Record Percent Increase
BofA Adjusts Price Target on Alamar Biosciences to $31 From $30
MT Newswires Live  ·  08-11
BofA Adjusts Price Target on Alamar Biosciences to $31 From $30

Introduction

Company Name.
Alamar Biosciences
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Alamar Biosciences, Inc. was incorporated in Delaware on May 7, 2018, and is headquartered in Fremont, California. The company is a commercial-stage proteomics company dedicated to establishing the gold standard in protein detection and analysis. It offers the proprietary NULISA platform, which enables "precision proteomics" by detecting low-abundance protein biomarkers in non-invasive biofluids with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and automation. The company provides integrated solutions comprising instruments, consumables, and analytical software for discovery, translational research, and diagnostic development.
Issue price:
--